Natera (NTRA) Stock Price
Natera Price
Revenue has compounded at 47.9% per year over the past 13 years to 2.31 B USD. Natera's net margin stands at -9.0%, up from -75.4% several years earlier. Analysts set a median price target of 335.00 USD, implying 21.3% below the current price. Of 30 analysts, 26 rate the stock a buy — an overall Buy consensus.
Natera stock price
Natera business model & stock analysis
Frequently asked questions about Natera
Natera Inc operates within the healthcare industry, specifically focusing on genetic testing and diagnostics. As a leading company in molecular diagnostics, Natera specializes in developing and commercializing genetic testing products that aid in reproductive health and oncology. These innovative products include non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT), and circulating tumor DNA analysis (ctDNA). Natera's business model revolves around providing physicians and patients with advanced genetic testing solutions to help inform medical decisions and improve patient outcomes. With a strong emphasis on research and technological advancements, Natera Inc aims to enhance the standard of care in genetic testing and prenatal screening.
Natera Inc is primarily active in the healthcare industry.
The main competitors of Natera Inc in the market include companies such as Illumina Inc, Invitae Corporation, and Myriad Genetics Inc.
Natera Inc, founded in 2004 and based in California, is a leading genetic testing and diagnostics company. Specializing in reproductive health and genetic disease screening, Natera aims to provide valuable insights for patients and healthcare providers. The company utilizes advanced technologies like cell-free DNA analysis and bioinformatics to develop innovative solutions. Natera's groundbreaking products cover diverse areas such as non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT), and genetic carrier screening. With a strong commitment to accuracy, reliability, and patient care, Natera Inc continues to pave the way in genetic testing, contributing to improved healthcare outcomes globally.
Natera Inc, a leading genomics company, has achieved significant milestones in its journey. The company has revolutionized non-invasive prenatal testing (NIPT) with its proprietary Panorama® test, providing accurate and early detection of chromosomal abnormalities. Natera Inc has also made remarkable progress in oncology with its Signatera™ personalized oncology assay, empowering clinicians to monitor treatment response and minimal residual disease. Furthermore, the company's ever-expanding menu of genetic tests, including carrier screening and hereditary cancer testing, has positioned it as a trusted partner in personalized healthcare. Natera Inc continues to drive innovation, harnessing the power of genomics to improve patient care and advance precision medicine.
Natera Inc is primarily present in various countries and regions around the world. This includes the United States, where the company is headquartered in San Carlos, California. Natera's presence also extends to other countries such as Canada, the United Kingdom, Germany, France, Spain, Italy, Australia, and many more. With its global reach, Natera Inc offers its innovative genetic testing and diagnostic solutions to individuals and healthcare providers in numerous regions, contributing to advancements in personalized medicine worldwide.
Natera Inc represents values of innovation, accuracy, and compassion in the field of biotechnology. The company is driven by a corporate philosophy focused on transforming the way diseases are detected, managed, and treated. With cutting-edge technology and a commitment to improving patient outcomes, Natera Inc aims to provide advanced genetic testing solutions that revolutionize healthcare. By consistently delivering high-quality diagnostic insights, personalized medicine, and reproductive health solutions, Natera Inc stands as a leader in the industry. Through ongoing research and development, the company strives to empower individuals and healthcare professionals with the knowledge and tools to make informed decisions and improve lives.
Analysts currently set an average price target of 319.00 USD for the Natera stock (median: 335.00 USD), implying -25.1 % versus the latest price. The consensus is based on 30 analyst ratings.
30 analysts currently rate the Natera stock: 26 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Natera to generate revenue of 2.91 B USD and earnings per share of -1.37 USD.
Converted at the current exchange rate, the Natera share trades at 379.72 EUR (425.64 USD).
The Natera share (NTRA) is listed on 2 stock exchanges, including: NASDAQ (NTRA), Frankfurt (45E.F).
Natera Inc. is an American biotechnology company based in San Carlos, California. The company focuses on the development and marketing of products and services in the prenatal and reproductive health, cancer diagnostics, and gene therapy fields.
The expected revenue of Natera is 2.91 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Natera is -187.50 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Natera is currently -310.37. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Natera stock.
The price-to-sales ratio (P/S) of Natera is currently 20.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Natera stock.
The Eulerpool Quality Score for Natera is 4/10.
The ISIN of Natera is US6323071042. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Natera is A14VPJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Natera is NTRA. The ticker symbol is used to trade Natera shares on the stock exchange.
Natera stock
Natera Ticker
Natera FIGI
All fundamentals and in-depth analysis of Natera
Our stock analysis for Natera stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Natera. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.